Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 16, 2025Psoriasis Targets and TherapyOpen Access

Long-Term Real-World Effectiveness and Drug Survival of Guselkumab in Patients with Psoriasis: A 5-Year Retrospective Study

View Full Paper
Ask AI
Bookmark
Share

Authors

EMEdoardo MortatoUniversity of Rome Tor VergataMTMarina TalamontiPoliclinico Tor VergataLMLorenzo MarcelliUniversity of Rome Tor Vergata

Discussion

Loading...

Member takes

Overview

Retrospective study found guselkumab maintains long-term effectiveness in psoriasis, with drug survival affected by obesity and prior biologic exposure.

Key Points

  • Guselkumab demonstrated sustained long-term efficacy in psoriasis, with significant PASI improvements over 5 years.
  • Mean PASI scores improved from 14.3 at baseline to as low as 1.0 at 12 months, indicating effective treatment.
  • Logistic regression identified previous biologic exposure and obesity as negative predictors of treatment response.
  • After 5 years, drug survival rates were high, showing 85.76% of patients remained on treatment.

Cite This Study

Mortato et al. (2025) studied this question.

synapsesocial.com/papers/68d46ccf31b076d99fa69018https://doi.org/10.2147/ptt.s533005
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Real‐life effectiveness and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: A 104‐week multicenter retrospective study – IL PSO ( ITALIAN LANDSCAPE PSORIASIS )2023 · 33 citations
  2. 2Guselkumab in moderate to severe psoriasis in routine clinical care: an Italian 44-week real-life experience2020 · 48 citations
  3. 3Short-Term Efficacy and Safety of IL-17, IL-12/23, and IL-23 Inhibitors Brodalumab, Secukinumab, Ixekizumab, Ustekinumab, Guselkumab, Tildrakizumab, and Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials2019 · 165 citations
  4. 4Five‐year maintenance of clinical response and health‐related quality of life improvements in patients with moderate‐to‐severe psoriasis treated with guselkumab: results from VOYAGE 1 and VOYAGE 2*2021 · 81 citations
  5. 5New Treatment Addressing the Pathogenesis of Psoriasis2020 · 269 citations